CD8A and neoplasm: To confirm if the anti-tumor effects of the UPs-4T1/EPB nanovaccine are dependent on induced CD4+ and CD8+ T cells, specific antibodies were used to deplete CD4+ and CD8+ T cells over the course of therapy (Figure 5A).